FDA Grants IND Approval for Novel Inhaled Interferon Treatment Against RSV in Children
• Kexing Biopharm's GB05, a novel inhaled interferon α1b solution, receives FDA approval to begin clinical trials for treating RSV infections in pediatric patients.
• The innovative treatment targets respiratory syncytial virus infections in children under five, addressing a significant unmet medical need with no currently approved antiviral drugs.
• GB05's unique formulation offers enhanced stability, improved safety profile, and better treatment compliance through inhalation delivery compared to traditional injection methods.
© Copyright 2025. All Rights Reserved by MedPath